(This is not a complete list of publications, but only a selection of the major ones.)


Rajewsky K, Schirrmacher V, Nose S, Jerne NK. The requirement of more than one antigenic determinant for immunogenicity. J Exp Med 1969, 129:1131-43. PMID: 4181830


Schirrmacher V. Shifts in tumor celi phenotypes induced by signals from the microenvironment. Relevance for the immunobiology of cancer metastasis. Immunobiology 1980, 157:89-98. PMID: 6967852


Heicappell R, Schirrmacher V, von Hoegen P, Ahlert T, Appelhans B. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. Int J Cancer 1986, 37:569-77. PMID: 3957462


Khazaie K, Prifti S, Beckhove P et al. Persistence of dormant tumor celis in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. Proc Natl Acad Science USA 1994, 91:7430-4. PMID: 8052600


Schirrmacher V, Beckhove P, Kruger A et al. Effective immune rejection of advanced metastasized cancer. IntJ Onco11995, 6:505-21. PMID: 21556565


Schirrmacher V, Forg P, Dalemans Wet 01. Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen. Gene Ther 2000,7:1137-47. PMID: 10918481


Feuerer M, Beckhove P, Bai L et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001, 7:452-8. PMID: 11283672


Bai L, Koopmann J, Fiola C et al. Dendritic cells pulsed with viral oncolysate stimulate autologous T-cells from cancer patients. Int J Oncol 2002, 21:685-94. PMID: 12239606


Feuerer M, Beckhove P, Garbi N et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 2003, 9:1151-7. PMID: 12910264


Steiner HH, Bonsanto MM, Beckhove P et al. Antitumor vaccination of patients with Glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 2004, 22:4272-81. PMID: 15452186


Sommerfeldt N, Schiitz F, Sohn C et al. The shaping of a polyvalent and highly individual T-cell repertoire in the bone marrow of breast cancer patients. Cancer Res 2006, 66:8258-65. PMID: 16912206


Schirrmacher V. Complete remission of cancer in late-stage disease by radiation and transfer of allogeneic MHC-matched immune T cells: lessons form GvL studies in animals. Cancer Immunol Immunother 2014,63:535-43. PMID: 24610041


Fournier P, Schirrmacher V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. Biodrugs 2013, 27:35-53. PMID: 23329400


Schirrmacher V. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy: A biological agent with potential to break therapy resistance. Exp Opin Bioi Ther 2015,15:1757-71. PMID: 26436571


Schirrmacher V. Fifty years of clinical application of Newcastle disease virus. Time to celebrate! Biomedicines 2016, 4(3), 16. PMID: 28536382


Schirrmacher V, Lorenzen D, Von Goal SW, Stuecker W. A new strategy of cancer immunotherapy combining hyperthermia/oncolytic virus pretreatment with specific autologous anti-tumor vaccination - A review. Austin Oncol Case Rep 2017, 2:1006.

to top
powered by webEdition CMS